In one paragraphArticle in ACS infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 4 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors at 1 institution in 1 country.
Pankaj S MahajanChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, United States.ORCID 0000-0002-6915-9082 Steven J SmithChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, United States.
Min LiNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States.
Robert CraigieNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States.
Stephen H HughesHIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, United States.ORCID 0000-0002-9176-4377 Xue Zhi ZhaoChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, United States.
Terrence R BurkeChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, United States.ORCID 0000-0001-9925-8586 National Institutes of Health · US
Funding
Studies of nucleoprotein complexes involved in retroviral DNA integrationZIADK036169 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI CRAIGIE, ROBERT · 2009 to 2025
$22.5MDesign and Synthesis of HIV Integrase as Potential Anti-AIDS DrugsZIABC007363 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BURKE, TERRENCE · 2009 to 2025
$11.7MPHARMACOLOGY OF THE HIV VIRAL DNA AND RETROVIRAL INTEGRASESZ01BC007333 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI POMMIER, YVES · 1996 to 2008
$1.0MIntramural NIH HHS Z01 BC007333Intramural NIH HHS ZIA BC007363
6 · The paper itselfAbstract
HIV-1 integrase (IN) is an important molecular target for the development of anti-AIDS drugs. A recently FDA-approved second-generation integrase strand transfer inhibitor (INSTI) cabotegravir (CAB, 2021) is being marketed for use in long-duration antiviral formulations. However, missed doses during extended therapy can potentially result in persistent low levels of CAB that could select for resistant mutant forms of IN, leading to virological failure. We report a series of
Indexed as
HIV IntegraseHIV Integrase InhibitorsPyridonesRaltegravir PotassiumHIV IntegraseHIV Integrase Inhibitorsp31 integrase protein, Human immunodeficiency virus 1PyridonesRaltegravir Potassiumbicyclic carbamoyl pyridone (BiCAP)cabotegravirHIV-1INSTIINSTI-resistanceone-pot synthesisresistant mutants
Identifiers
PMID38346249
PMCPMC10928719
OpenAlexW4391757099
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390